In in vivo multiple myeloma models, shRNA-mediated Gal-1 inhibition downregulated pro-angiogenic genes, including MMP9 and CCL2, and upregulated the anti-angiogenic SEMA3A and CXCL10. The gene discussed is LGALS1; the disease is plasma cell myeloma.